India to Tanzania: Ambroxol Export Trade Route

Importers must register their premises with TMDA prior to applying for import permits. Applications for import permits should be submitted at least six weeks before loading the consignment to avoid storage and disposal costs. The importation permit is valid for six months. Processing of special applications for importation of pharmaceuticals cannot exceed ten working days, provided the application meets all requirements. (tmda.go.tz)

The TMDA requires that imported pharmaceutical products be registered and issued with a Product Registration Certificate before being placed on the market. The application for product registration should include a Common Technical Document (CTD) dossier. The TMDA conducts Good Manufacturing Practice (GMP) inspections of manufacturing facilities to ensure compliance with quality standards. (tic.go.tz)

Indian exporters of Ambroxol formulations must comply with TMDA's GMP standards. The TMDA conducts GMP inspections of pharmaceutical manufacturing facilities to assess compliance with GMP requirements. Foreign manufacturing facilities must be registered by their respective National Medicines Regulatory Authorities before applying to be inspected by TMDA. The application should be submitted online and must be accompanied by proof of payment of GMP inspection fees and the current site master file. (tmda.go.tz)

The TMDA maintains a list of foreign pharmaceutical manufacturing facilities that are compliant with GMP requirements. It is essential for Indian exporters to ensure their manufacturing facilities are included in this list to facilitate the importation process. (tmda.go.tz)

In January 2024, India's Ministry of Health revised the Good Manufacturing Practices (GMP) regulations under Schedule M of the Drugs and Cosmetics Rules. The term 'Good Manufacturing Practices' was replaced with 'Good Manufacturing Practices and Requirements of Premises, Plant and Equipment for Pharmaceutical Products.' The revised rules introduced a pharmaceutical quality system (PQS), quality risk management (QRM), product quality review (PQR), qualification and validation of equipment, and a computerized storage system for all drug products. These changes aim to align India's GMP standards with global standards, especially those of the World Health Organization (WHO).

As of March 2026, there have been no reported regulatory changes, new guidelines, mutual recognition agreements, or policy shifts by the TMDA affecting Indian pharmaceutical exports to Tanzania in the past 18 months.

Ambroxol, a mucolytic agent used to treat respiratory conditions, is in demand in Tanzania due to the prevalence of respiratory diseases. The country's healthcare spending has been increasing, with a focus on improving access to essential medicines. While specific market size data for Ambroxol formulations in Tanzania for 2024-2025 is not readily available, the import data indicates a reliance on foreign suppliers, particularly from India. Domestic manufacturing of Ambroxol formulations appears limited, necessitating imports to meet patient needs.

Tanzania imposes a 0% Most-Favored-Nation (MFN) import duty on pharmaceutical products classified under HS code 30049099, which includes Ambroxol formulations. Additionally, these products are exempt from the 2% Railways Development Levy (RDL) and the 0.6% Destination Inspection Fee, further facilitating their importation. There are no specific Free Trade Agreements (FTAs) between India and Tanzania that affect pharmaceutical tariffs, nor are there any anti-dumping duties imposed on these imports.

India is the primary supplier of Ambroxol formulations to Tanzania, accounting for a significant portion of the imports. Other countries may also export these products to Tanzania, but their market share is comparatively smaller. India's competitive pricing and established pharmaceutical manufacturing capabilities contribute to its dominant position in the Tanzanian market. While specific pricing comparisons between India and competitors like China or European Union manufacturers are not detailed here, India's cost-effective production and favorable trade terms likely offer advantages over other suppliers.

India is a leading global producer of generic pharmaceuticals, accounting for approximately 20% of the global supply by volume as of 2024. The country's pharmaceutical industry is supported by a vast network of manufacturing facilities, including over 1,400 plants registered with the U.S. Food and Drug Administration (FDA) as of November 2024. This includes 396 facilities dedicated to finished dosage forms (FDFs), ensuring a robust capacity for producing formulations containing Ambroxol. Additionally, India's cost-effective manufacturing processes, driven by economies of scale and a skilled workforce, enable competitive pricing for Ambroxol tablets, capsules, and syrups. The presence of numerous WHO-GMP and FDA-approved facilities underscores India's commitment to quality and regulatory compliance in pharmaceutical production.

When comparing Ambroxol formulations from India, China, and the European Union (EU), several factors emerge:

• Price per Unit: Indian manufacturers offer Ambroxol formulations at an average export price of $0.49 per unit under HS Code 3004, as of November 2016. In contrast, Chinese manufacturers have experienced a decline in Ambroxol sales, with a 34% drop in 2020 compared to 2019, indicating potential pricing pressures. EU-produced Ambroxol formulations, often branded generics, typically command higher prices due to stringent regulatory standards and higher production costs.

• Quality Perception: Indian pharmaceutical products are widely accepted in Tanzania, with Indian manufacturers holding a significant share of the market. The presence of WHO-GMP and FDA-approved facilities in India reinforces the quality and safety of its pharmaceutical exports.

• Regulatory Acceptance in Tanzania: Tanzania's regulatory framework recognizes and approves pharmaceuticals from India, facilitating smoother import processes. The established trade relationship between the two countries further supports this acceptance.

• Supply Reliability Track Record: Indian pharmaceutical companies have a strong track record of fulfilling international orders reliably. The extensive manufacturing infrastructure and experience in global distribution contribute to consistent supply chains.

The India-Tanzania supply chain for Ambroxol formulations is characterized by:

• Manufacturing Capacity: India's pharmaceutical sector includes numerous facilities capable of producing large volumes of finished dosage forms, ensuring the ability to meet substantial demand.

• Packaging and Cold Chain Capabilities: Indian manufacturers possess advanced packaging technologies and robust cold chain logistics, ensuring the stability and efficacy of Ambroxol formulations during transit.

• Regulatory Compliance Track Record: Indian pharmaceutical companies maintain high standards of regulatory compliance, with many facilities holding WHO-GMP and FDA approvals, ensuring adherence to international quality standards.

• Capacity Constraints or Expansion Plans: Leading Indian manufacturers continually invest in expanding their production capacities and upgrading facilities to meet growing global demand, indicating a proactive approach to capacity management.

For Tanzanian buyers sourcing Ambroxol formulations from India, the following strategies are recommended:

• Dual-Sourcing Strategy: Engage with multiple Indian suppliers to mitigate risks associated with supply disruptions and ensure a consistent supply of Ambroxol formulations.

• Minimum Order Quantities (MOQs): Negotiate MOQs that align with your demand forecasts and storage capabilities, as Indian manufacturers may offer flexibility based on order volumes.

• Payment Terms: Familiarize yourself with common payment terms in India-Tanzania pharmaceutical trade, such as Letters of Credit (LC) or advance payments, to establish mutually agreeable terms with suppliers.

• Supplier Qualification Process: Implement a thorough qualification process, including audits and compliance checks, to ensure suppliers meet Tanzanian regulatory requirements and maintain high-quality standards.

• Regulatory Compliance: Ensure that selected suppliers have the necessary certifications and approvals, such as WHO-GMP, to facilitate smooth importation and distribution within Tanzania.

By meticulously following these guidelines, Tanzanian companies can ensure that Ambroxol formulations sourced from Indian manufacturers meet the highest standards of quality and regulatory compliance.